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Cardiac resynchronization therapy (CRT) is an established treatment for symptomatic patients with heart failure, a prolonged QRS duration,
and impaired left ventricular (LV) function. Identiﬁcation of ‘responders’ and ‘non-responders’ to CRT has attracted considerable attention.
The response to CRT can be measured in terms of symptomatic response or clinical outcome, or both. Alternatively, the response to CRT
can be measured in terms of changes in surrogate measures of outcome, such as LV volumes, LV ejection fraction, invasive measures of
cardiac performance, peak oxygen uptake, and neurohormones. This review explores whether these measures can be used in assessing
the symptomatic and prognostic response to CRT. The role of these parameters to the management of individual patients is also discussed.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Cardiac resynchronization therapy † Mortality † Responders
Introduction
Cardiac resynchronization therapy (CRT) was unveiled as a new
therapy by the pioneering work of Cazeau et al.
1 who, in 1994,
reported the dramatic clinical improvement of a 54-year-old man
in severe heart failure treated by four-chamber pacing. Later in
an acute study, Leclercq et al.
2 showed that temporary CRT
increases left ventricular (LV) stroke volume and reduces pulmon-
ary capillary wedge pressure. Auricchio’s group, further, showed
that CRT increases LV dP/dt.
3 In 2001, the Multisite Stimulation
in Cardiomyopathies (MUSTIC) study, in the ﬁrst randomized con-
trolled cross-over trial design in the ﬁeld of resynchronization
therapy, found that CRT dramatically reduced heart failure hospi-
talizations and improved NYHA class, as well as quality of life,
exercise distance, and peak oxygen uptake (peak VO2).
4 More
recently, the Cardiac Resynchronization in Heart Failure
(CARE-HF) trial indicated that CRT-pacing (CRT-P) led to a 36%
relative reduction in total mortality compared with medical
therapy.
5 The comparison of medical therapy, pacing, and deﬁbril-
lation in heart failure (COMPANION) study showed that addition
of a cardioverter deﬁbrillator (CRT-D) to CRT also led to
additional survival beneﬁts compared with CRT-P.
6
Response to CRT has become critically important as it is con-
sidered in a different way from that with drug therapy of heart
failure. With drugs, patients are up-titrated to the doses used in
major outcome trials without the need for measuring symptomatic
response or predictors of outcome in routine clinical settings.
Possibly, the insistence on deﬁning CRT response in the same set-
tings reﬂects both the high initial cost of the pacing system and the
need for a surgical procedure to implant it. If measurement of
response and outcome in CRT is necessary, outcome variables
must surely provide ‘a valid and reliable measure of some clinically
relevant and important treatment beneﬁt in the patient popu-
lation’.
7 Ultimately, the ﬁnal objective must be to prolong survival
and/or to alleviate symptoms as well as to improve quality of life.
This review focuses on parameters that have so far been used to
deﬁne a response to CRT. The relevance of these parameters to
the management of individual patients is also discussed.
Outcome and response
Outcome
In order to estimate the effects of CRT on survival, patients’ life-
times must be considered rather than the follow-up period of a
study. The 2007 United Kingdom National Institute of Clinical
Excellence (NICE) Health Technology Appraisal (HTA) on CRT
provided an extensive analysis of CRT-P, CRT-D, and optimum
pharmacological therapy (OPT) alone over patients’ lifetimes
(Table 1).
8 According to these analyses, the median survival after
device implantation is 4.62 years for CRT-P and 5.15 years for
CRT-D. However, the additional life gained must be compared
with OPT and amounts to a median of 0.85 years for CRT-P and
1.39 years for CRT-D.
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characteristics inﬂuence the outcome of CRT.
8 Age at the time of
implantation, for example, has a signiﬁcant impact: the additional
life gained from CRT-P, compared with OPT alone, was a
median of 1.69 years for 40 year olds and only 0.54 years for
80 year olds. The additional life gained from CRT-D was 3.08
and 1.23 years, respectively. The addition of a deﬁbrillation
capacity to the device makes an important difference at all ages.
8
For 50 year olds, the proportional increase in overall median sur-
vival was 23% for CRT-P and 41% for CRT-D, compared with
OPT. Other studies have shown that outcome of CRT also
depends upon the NYHA class prior to implantation,
9–11 the
aetiology of the heart failure,
12 and the atrial rhythm.
13
In observational studies, the criterion for survival with CRT has
arbitrarily been set at 1 year of life following implantation.
14–16
Rather than adopting such arbitrary cut-offs, patients could be con-
sidered ‘prognostic responders’ to CRT if their actual survival
matches that expected from modelling analyses, taking into
account patient- and device-related variables. This methodology,
which is yet to be applied, is anticipated to be more precise than
using the same arbitrary cut-offs for all patients.
Response
It is often quoted that CRT has a ‘non-responder’ rate of up to
30%, implying that a responder rate of anything lower than 100%
is unsatisfactory. Similar ﬁgures, however, emerge for drug
therapy if the same approach is adopted. In the results of the
Cooperative North Scandinavian Enalapril Survival Study (CON-
SENSUS), 46.7% of patients treated with enalapril improved by
 1 NYHA class.
17 In the Cardiac Insufﬁciency Bisoprolol Study
(CIBIS), 21% of patients treated with bisoprolol improved by  1
NYHA class.
18 In the Randomized Aldactone Evaluation Study
(RALES), 41% of patients treated with spirinolactone improved
by  1 NYHA class.
19 Accordingly, the ‘non- responder’ rates in
these studies were 53.3% for enalapril, 79% for bisoprolol, and
59% for spironolactone. To quantify the true additional effect of
a treatment, it is necessary to compare the new therapy with con-
trols. Adopting an improvement by  1 NYHA class as the deﬁ-
nition of response, the ‘responder’ rate for placebo was 21.8% in
the CONSENSUS study, 15% in the CIBIS study, and 33% in the
RALES study. Accordingly, the response to treatment, compared
with placebo, was 24.9% for enalapril, 6% for bisoprolol, and 8%
for spironolactone.
The symptomatic response to CRT can be quantiﬁed in random-
ized, controlled trials, but what should be considered to be an ade-
quate response to CRT in individual patients? With reference to
the CARE-HF study, CRT was associated with a reduction in
NYHA class from 3.06 at baseline to 2.1 at 90 days post-
implantation.
5 With respect to quality of life, the COMPANION
study showed an improvement by 8.8% with CRT-P, 9.3% with
CRT-D, and 3.7% with medical therapy alone.
6 Therefore, a
reduction by approximately one NYHA class and an improvement
in quality of life by 5 to 6% is what should CRT-P or CRT-D be
expected to achieve in the ‘average’ patient.
Discordance between outcome
and response
A favourable symptomatic response to a treatment does not
necessarily parallel a favourable outcome. At one extreme, pallia-
tive treatments improve symptoms but do not prolong survival.
At the other, chemotherapy for cancer prolongs survival, but
causes symptoms and worsens quality of life. It should also be con-
sidered that, if given the choice, some patients prefer symptomatic
beneﬁt to prognostic beneﬁt, particular if they are severely limited
by symptoms.
As for most treatments for heart failure, symptomatic and prog-
nostic beneﬁts from CRT are not necessarily concordant. This was
suggested by Yu et al.,
20 who found similar improvements in
NYHA class, 6 min walk distance and quality of life at 3–6
months in survivors and non-survivors treated by CRT. These ﬁnd-
ings raise problems in clinical practice. For example, should CRT be
modiﬁed or withdrawn in a patient who has improved symptoma-
tically but in whom a surrogate measure of outcome predicts a
shortened survival? So far, this question is unanswered.
Surrogate markers of outcome
A surrogate endpoint should be a true predictor of disease, not
reﬂection of a co-variable.
21 To be clinically useful, a surrogate
measure of outcome must be measurable and reproducible by
different observers and by different centres. It should be reliable,
available, and easily quantiﬁable. The relationship between a surro-
gate and the true endpoint should be also validated internally,
22
within the population from which it is derived, and externally by
other centres. In addition, P-values should not be considered to
be the sole arbiter in a study. A P , 0.05 does not mean that
the sample size is adequate, that the effect size is clinically mean-
ingful, or that the parameter in question has discriminatory
ability.
23 Diagnostic utility should be tested using Bayesian analyses.
Cut-offs should be sensitive and speciﬁc (.90% for both), with a
clear distinction between what is normal or abnormal.
In an ideal world, the surrogate endpoint is mechanistically
linked to the true endpoint via a single pathway and the surrogate
.................................... ........................
................................................................................
Table 1 Survival from CRT-P and CRT-D over a
patients’ lifetime
Age
b Survival Additional life
a
OPT CRT-P CRT-D CTR-P CRT-D
30 7.31 9.00 10.39 1.69 3.08
40 7.23 8.92 10.31 1.69 3.08
50 7.15 8.76 10.08 1.62 2.92
60 6.15 7.15 8.00 1.00 1.85
70 4.46 5.39 5.85 0.92 1.39
80 3.08 3.77 4.31 0.54 1.23
90 2.31 2.69 2.92 0.39 0.62
Overall 3.77 4.62 5.15 0.85 1.39
All values are expressed as medians (years).
Reproduced with permission from the Peninsula Technology Assessment Group.
8
aRefers to survival advantage over optimum medical therapy alone (OPT).
bAge at the time of implantation.
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is affected by the intervention. In practice, however, the pathophy-
siological processes linking the cause and the surrogate are mani-
fold, as are the processes linking the surrogate endpoint and the
true endpoint (Figure 1). These complex interactions between bio-
logical variables often underlie the difﬁculty in identifying reliable
surrogate endpoints.
Reverse left ventricular remodelling
Cardiac remodelling is the ﬁnal common pathway of chamber dila-
tation and failure that occurs after myocardial infarction, pressure
overload, inﬂammatory muscle disease, idiopathic dilated
cardiomyopathy, or volume overload.
24 Left ventricular remodel-
ling has been linked to poor long-term prognosis in patients with
heart failure.
24–26 Reverse LV remodelling, on the other hand,
has been demonstrated with drugs that are known to beneﬁt




in LV end-systolic volume (LVESV) appears to be the most useful
measure of reverse remodelling.
26
Numerous studies have shown signiﬁcant reduction in LVESV
after CRT.
20,30–32 Such reductions are evident as early as
1 month post-implantation,
33 and are sustained at 29 months.
5
Further support for a causative link between CRT and reverse
LV remodelling is suggested by the ﬁnding of LV dilatation when
CRT is withdrawn.
34 The value of reverse LV remodelling in discri-
minating prognostic ‘responders’ and ‘non-responders’ to CRT was
explored in a study of 141 patients, in which a reduction in LVESV
 9.5% 3 to 6 months post-implantation was identiﬁed as a predic-
tor of all-cause (P ¼ 0.0003) and cardiovascular (P , 0.0001) mor-
tality.
20 There is, in addition, evidence to indicate that the
magnitude of reverse LV remodelling relates to the clinical
outcome. In this respect, Ypenburg et al.
35 found that in patients
undergoing CRT, all-cause mortality was 3% in patients with a
LVESV reduction of  30% and 21% in patients with a LVESV
reduction between 0 and 14%. This goes some way towards satis-
fying another desirable characteristic of surrogate endpoints,
namely, that they should relate linearly to the true endpoint.
36
On the basis of the above, reverse LV remodelling is a promising
surrogate measure of outcome after CRT. Cut-offs of reverse LV
remodelling must, however, clearly differentiate between good
and poor outcome. They must, therefore, withstand the rigour
of Bayesian analyses. One of the few studies to employ this meth-
odology showed that a reduction in LVESV  9.5% predicted all-
cause mortality with a sensitivity of 70% and a speciﬁcity of 70%,
and cardiovascular mortality with a sensitivity of 87% and a speci-
ﬁcity of 69% (Figure 2).
20 While these ﬁgures compare favourably
with other biomarkers, it must be noted that a sensitivity of 70%
means that 30% of patients, who beneﬁt prognostically from
CRT, are wrongly classiﬁed as ‘non-responders’. A speciﬁcity of
69% means that 31% of patients, who do not beneﬁt prognosti-
cally, are wrongly classiﬁed as ‘responders’. With this discrimina-
tory ability, it would appear that reduction in LVESV is of limited
value in discriminating between ‘responders’ and ‘non-responders’
after CRT. As a further limitation of studies of LV remodelling in
relation to CRT, none has used the statistical methodology of
internal and external validation.
22
Although reverse LV remodelling relates to outcome, it does
not relate to symptomatic response. In a study of 141 patients
undergoing CRT, Yu et al.
20 found no relationship between
reduction in LVESV and changes in NYHA class, 6 min walk dis-
tance, or quality of life score after CRT. Likewise, Ypenburg
et al.
35 found similar improvement in NYHA class, quality of life
score, and 6 min walk distance in patients exhibiting  15%
reduction in LVESV compared with those exhibiting a reduction
in LVESV of ,14%. Laﬁtte et al.
37 showed that 63% of patients,
who did not show a  15% reduction in LVESV following CRT,
nevertheless made clinical improvement. A clinician may, therefore,
encounter a patient, who has improved symptomatically after CRT,
Figure 1 Relationship between disease processes, interven-
tions, surrogate endpoints, and true clinical outcome. (A) The
ideal situation, which offers the greatest potential for the surro-
gate to be valid; (B) the surrogate is not in the aetiological
pathway of the disease; (C) the intervention affects only the
pathway mediated through the surrogate, but there are other
aetiological pathways; (D) the intervention does not affect the
surrogate; (E) the mechanism of action of the intervention is
independent of the disease process. Dotted lines represent
other possible mechanisms of action. Adapted with permission
from Fleming TR and DeMets DL.
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whether the absence of reverse remodelling, even on the back-
ground of clinical improvement, should prompt further interven-
tion, e.g. atrioventricular and ventricular-ventricular optimization,
lead repositioning or withdrawal of therapy.
The discordance between symptoms and reverse LV remodel-
ling after CRT is not unexpected, given that CRT acts via multiple
pathways. Diastolic ventricular interaction, which is demonstrable
in patients with heart failure,
38 is relieved by CRT.
39 In addition,
CRT reduces functional mitral regurgitation,
40 an effect which is
not wholly dependent on reverse LV remodelling.
41 Blood
ﬂow,
42 heart failure aetiology,
43 location of myocardial scarring,
44
and atrial rhythm
13 may also inﬂuence the outcome of CRT. In
addition, it has been shown that withdrawal of CRT in patients
who had exhibited progressive LV remodelling was associated
with a reduction in blood pressure and cardiac output
45
(Figure 3). This suggests that CRT confers a favourable haemo-
dynamic proﬁle, even on the background of progressive cardiac
remodelling.
Left ventricular ejection fraction
The notion that LV systolic function relates to the prognosis of
heart failure is mechanistically attractive. In this respect, the
Vasodilator-Heart Failure Trials (V-HeFT I and II) identiﬁed LVEF,
measured using radionuclide imaging, as a predictor of mortality
in male patients with heart failure.
46 Improvements in LVEF with
Figure 2 Reciever-operating curves for predicting all-cause (A)
and cardiovascular (B) mortality by LV reverse remodelling, as
reﬂected by the reduction in LVESV (dark line) and LVEDV
(light line). Reproduced with permission from Yu CM, et al.
20
Figure 3 Acute haemodynamic changes in patients with
CRT-on and CRT-off. Changes pertain to patients with advanced
decompensated heart failure who had undergone CRT implan-
tation at least 3 months prior to testing. A signiﬁcant worsening
of haemodynammics was observed immediately after CRT was
programmed off. Reproduced with permission from Mullens
et al.
45
What is treatment success in CRT? v61treatment have also been linked to improved prognosis.
46,47 In
some studies, however, drugs, which are known to prolong survi-
val, such as carvedilol
48 and enalapril
49 do not signiﬁcantly alter
LVEF (Figure 4). Conversely, bucindolol does increase LVEF, but
does not prolong survival.
50
In the CARE-HF trial, LVEF at 3 months increased by 4.7% in the
CRT-P arm, compared with 0.3% in OPT arm.
51 In multivariate
analyses, however, improvements in LVEF did not emerge as an
independent predictor of outcome. The demonstration of an
increase in LVEF by CRT, therefore, does not endorse the use of
LVEF as a predictor of beneﬁt from CRT. It should also noted
that, in patients with heart failure, LVEF relates poorly to symp-
toms.
52 Furthermore, the value of LVEF in monitoring patients
with heart failure has not been addressed by randomized studies,
nor has it been validated, with regard to CRT, nor any other treat-
ment. On this basis, echocardiographically derived LVEF is an unli-
kely surrogate measure of outcome in CRT patients.
Other echocardiographic variables
On the basis that cardiac dyssynchrony is the substrate for effective
CRT, some echocardiographic studies have adopted dyssynchrony
measures, such as the septal-to-posterior wall motion delay and
the interventricular mechanical delay, as study endpoints.
53 Yet,
these measures have been proven not to relate to clinical improve-
ment after CRT.
54 No studies have validated whether correction of
dyssynchrony translates into an improved response or outcome
after CRT.
Haemodynamics
As for LVEF, improvements in the haemodynamic proﬁle should,
intuitively, qualify as a measure of response and outcome after
CRT. While, undoubtedly, CRT causes a haemodynamic improve-
ment in the acute setting,
2,3 no studies have explored whether this
is predictive of long-term response or outcome. Treatments,
which improve cardiac function, do not necessarily lead to a prog-
nostic beneﬁt. A trial comparing hydralazine and nitrates with an
ACE-inhibitor showed that, despite similar haemodynamic
effects, mortality was lower with the ACE inhibitor.
55 On this
basis, haemodynamic variables cannot be used as predictors of
long-term response or outcome after CRT.
Peak oxygen uptake
Peak VO2 is regarded as the gold standard prognostic marker in
patients with heart failure. One of the earliest studies to analyse
peak VO2 in relation to outcome in patients with heart failure
was that of Mancini et al.
56 According to the study protocol,
patients with a peak VO2 .14 mL/kg/min were denied transplan-
tation, whereas those with a peak VO2   14 mL/kg/min were
offered transplantation. The study demonstrated that peak VO2
could be used to identify patients in whom cardiac transplantation
could be safely delayed. However, as mortality and transplantation
were inﬂuenced by the study protocol, the ﬁndings cannot be
taken as validation of peak VO2 as a predictor of mortality in
patients with heart failure. In a similar study of patients referred
for cardiac transplantation, Aaronson et al.
57 found that normalized
peak VO2 predicted survival, but the area under the receiver-
operator characteristic curve (ROC) was only 0.66. In a study of
644 patients, Myers et al.
58 found that peak VO2 predicted mor-
tality, but the ROC area was only 0.64 (Figure 5). In addition,
these authors could not identify an optimal cut-off point for pre-
dicting survival. Several studies have shown that peak VO2 does
not predict survival in patients with heart failure.
59–61 With
regard to peak VO2 in relation to symptoms, Wilson et al.
62
found no relation between peak VO2 and quality of life, and only
a weak correlation between peak VO2 and a dyspnoea/fatigue
index. In this study, up to 45% of patients with a peak VO2
,14 mL/kg/min had few or no exertional symptoms. It would
appear, therefore, that peak VO2 is not a reliable measure of
Figure 4 Effect on ejection fraction of carvedilol and placebo in
the Australia-New Zealand (ANZ) carvedilol study,
48 enalapril
and placebo in the SOLVD study.
49
Figure 5 Receiver-operating curves for peak VO2 in relation to
3 year survival. The area under the curve was signiﬁcantly greater
for peak VO2 than for age and ejection fraction (P , 0.05).
Reproduced with permission from Myers et al.,
58 EF, left ventricu-
lar ejection fraction.
P.W.X. Foley et al. v62response or a predictor of outcome in unpaced patients with heart
failure.
An increase in peak VO2, ranging from 0.6
63 to 1.4 mL/kg/min
has been reported in relation to CRT.
64 Although this conﬁrms
that CRT has an effect upon cardiopulmonary and metabolic
status, it does not equate to validation of peak VO2 as a surrogate
measure of response or outcome. As a practical issue, temporal
changes in peak VO2 in individual patients are highly unpredict-
able.
65 This should be taken into account in interpreting the ﬁnd-
ings of studies such as RethinQ study, in which, interestingly,
patients with narrow QRS complexes undergoing CRT exhibited
an improvement in NYHA class, but not in peak VO2.
66
Walk distance
The 6 min walk test (6-MWT) has been adopted as a measure of
response to CRT in a number of studies. In a study of 1077 patients
with heart failure, Ingle et al.
67 found a negative correlation
(r ¼ 20.55; P ¼ 0.0001) between changes in symptoms and
changes in 6-MWT distance (i.e. a reduced 6-MWT distance is
associated with reduced symptom severity at follow-up). On this
basis, the 6-MWT provides a reproducible
68 measure of sympto-
matic status in patients with heart failure. In a systematic review,
the 6-MWT distance was shown to concur with changes in heart
failure symptoms, particularly in the context of CRT.
69
As well as providing an additional measure of symptomatic
status, 6-MWT distance has been shown to relate to survival in
unpaced patients with heart failure.
60,70 In patients undergoing
CRT, pre-implant a 6-MWT distance ,225 m has been shown
independently to predict cardiovascular mortality.
71 Further
studies are needed to validate that the absolute 6-MWT distance
or change from baseline after implantation also translates into
poor outcome.
Neuroendocrine data
The observation that circulating natriuretic peptide levels change
with drug treatment
72,73 raises the possibility that they may be
good surrogate markers of outcome after CRT. In a study of
50 patients undergoing CRT, Pitzalis et al.
74 observed that at
1 month post-implantation, brain natriuretic peptide (BNP) was
lower in patients who had experienced no progression of heart
failure, compared with those who did. Further data from the
CARE-HF study showed that N-terminal (NT)-pro-BNP 3 month
post-implantation predicted long-term outcome (HR 5.7 for
patients in the highest tertile compared with those in the lowest
tertile).
51
Although natriuretic peptides relate to the clinical outcome of
CRT, their very high variability is likely to compromise their use
as surrogate markers of outcome during clinical follow-up. In
healthy individuals, serial changes of up to 92% for NT pro-BNP
and up to 168% for BNP have been reported.
75 In patients with
heart failure, the intraindividual coefﬁcient of variation can be as
high as 35% from week to week.
76 To be useful as a marker of
response, one must deﬁne what reduction in natriuretic peptides
post-implantation relates accurately to a future survival beneﬁt in
individual patients. To date, however, the magnitude of this
reduction has not been determined, nor validated. Post-implant
changes in natriuretic peptides, therefore, cannot be taken as
reliable surrogate markers of long-term outcome after CRT.
Ventricular arrhythmias
Ventricular ectopy was once considered a surrogate of prognostic
beneﬁt following a myocardial infarction. Drugs which reduce ven-
tricular ectopy, such as ﬂecainide,
77 however, were subsequently
found to shorten survival. Similarly, amiodarone controls ventricu-
lar tachycardia, but has no effect on survival. Early studies showed
that CRT reduces ventricular ectopy
78 and device delivered antita-
chycardia therapy.
79 These ﬁndings may be relevant to those of the
CARE-HF extension study, in which reduction in sudden cardiac
death following CRT was found.
80 Importantly, such an effect
was not apparent after the initial 29 months’ follow-up.
5 It
follows, therefore, that even if ventricular arrhythmias were good
predictors of sudden cardiac death after CRT, they would be unli-
kely to be predictors of survival beneﬁt.
Composite measures
As discussed earlier, single measures are unlikely to be reliable pre-
dictors of the outcome of CRT in the complex syndrome of heart
failure. The rationale for using composite measures stems from the
fact that heart failure has many effects: it causes death, hospitaliz-
ation, exercise intolerance, breathlessness, and a worsening in
quality of life. The attraction of a composite endpoint, or score,
is that it allows the reduction of a disease’s varied effects into a
single, measurable parameter. By strengthening the capacity to
pick out weaker signals from the background noise of sampling
error, combined endpoints improve the decisiveness of a clinical
trial.
23 In clinical practice, composite clinical scores
81 could
include variables which, together, amount to a clinically meaningful
measure. The difﬁculty lies in choosing what to measure and in
deciding on the relative importance of each measure.
82 For
example, should a reduction in LVESV be treated with equal
importance (or weighting) as an improvement in NYHA class, or
avoidance of hospitalization, or death? The 9th Clinical Trialists
Workshop of the US National Institutes of Health and other regu-
latory bodies concluded that standards for weighting composite
scores were needed; that consensus was needed to deﬁne a clini-
cally meaningful effect of composite scores, and that the value of
the ‘trade-off’ position between components of composite
scores needs to be deﬁned.
83 These issues are yet to be addressed
in the ﬁeld of CRT. Arguably, they should be a priority for regulat-
ory bodies.
Conclusions
In summary, CRT has revolutionized the treatment of selected
patients with heart failure. Although reverse LV remodelling is a
promising surrogate of outcome after CRT, one should consider
that volumetric ‘non-responders’ may nevertheless experience
symptomatic beneﬁt. On the other hand, patients who beneﬁt
symptomatically may not necessarily derive a prognostic beneﬁt.
As for most heart failure therapies, reliable measures of response
to CRT in individual patients are yet to emerge. Composite
measures may hold the key. Such measures must be validated
against the survival and symptomatic beneﬁts that are to be
What is treatment success in CRT? v63expected from therapy in individual patients, on the basis of ran-
domized, controlled trials. In addition, composite clinical endpoints
must reﬂect the relative importance of response and outcome
beneﬁts, as judged by patients, not doctors. Until this is established,
the terms ‘responder’ and ‘non-responder’ to CRT have little
meaning in clinical practice.
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